Patterson Companies (PDCO) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
9 Jul, 2026Executive summary
Fiscal 2024 net sales rose 1.5% year-over-year to $6.57 billion; Q4 net sales up 0.1% to $1.72 billion.
Adjusted EPS was $0.82 for Q4 and $2.30 for the full year; GAAP EPS was $0.74 for Q4 and $1.98 for the year.
Returned $327.9 million to shareholders via dividends and share repurchases in fiscal 2024.
Q4 and full-year results were impacted by lower equipment sales and a $0.04 per share hit from the Change Healthcare cyberattack.
Strategic investments in software, technology, and value-added services advanced capabilities and are expected to drive long-term growth.
Financial highlights
Q4 gross margin was 21.5% (GAAP), 21.8% (adjusted); operating margin 5.1% (GAAP), 6.0% (adjusted).
Fiscal 2024 gross margin was 21.0% (GAAP), 21.2% (adjusted); operating margin 3.9% (GAAP), 4.6% (adjusted).
Q4 adjusted net income was $74.4 million ($0.82/share), down from $82.4 million ($0.84/share) last year.
Fiscal 2024 net income attributable to the company was $185.9 million, down from $207.6 million in fiscal 2023.
Free cash flow for fiscal 2024 was $171.3 million, down from $179.8 million in fiscal 2023.
Outlook and guidance
Fiscal 2025 GAAP EPS guidance: $2.00–$2.10; adjusted EPS: $2.33–$2.43, implying ~3% growth at midpoint.
Guidance assumes low single-digit sales growth, roughly flat operating margin, and stable market conditions.
Adjusted guidance excludes ~$29.1 million in deal amortization ($0.33 per share).
Change Healthcare disruption expected to have a modest negative impact in early fiscal 2025, with improvement by Q4.
Guidance excludes unplanned share repurchases, future acquisitions, and certain non-recurring items.
Latest events from Patterson Companies
- Q2 sales rose 1.3%, but earnings fell as dental weakness and strategic review shape outlook.PDCO
Q2 20258 Jul 2026 - Q1 sales and earnings declined on macro and cyberattack impacts, but guidance was reaffirmed.PDCO
Q1 202523 Jan 2026 - Q3 sales and earnings declined as merger closure and cyberattack impact loomed.PDCO
Q3 20256 Jun 2025